Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31852251 | 1.00 | GABRA1 (0.50) | GABRA1GABRB2CYP3A4GABRG2GABRB3 | |
| SCHEMBL15903486 | 0.83 | ACHE (0.43) | GABRA1GABRB2CYP3A4ACHEIDO1 | |
| SCHEMBL9263390 | 0.80 | GABRA1 (0.43) | GABRA1GABRB2CYP3A4GABRG2GABRB3 | |
| SCHEMBL21216509 | 0.79 | ACHE (0.40) | GABRA1GABRB2CYP3A4HIF1AACHE | |
| SCHEMBL23139487 | 0.79 | PDE2A (0.48) | CYP3A4LMNACYP1A2HIF1AACHE | |
| SCHEMBL24988976 | 0.79 | ACHE (0.40) | GABRA1GABRB2CYP3A4HIF1AACHE | |
| SCHEMBL21670120 | 0.79 | ACHE (0.40) | GABRA1GABRB2CYP3A4HIF1AACHE | |
| SCHEMBL20809861 | 0.79 | ACHE (0.40) | GABRA1GABRB2CYP3A4HIF1AACHE | |
| SCHEMBL20809865 | 0.79 | ACHE (0.40) | GABRA1GABRB2CYP3A4HIF1AACHE | |
| SCHEMBL1004400 | 0.79 | ACHE (0.40) | GABRA1GABRB2CYP3A4HIF1AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343695-A1 | Lysophosphatidic Acid Receptor 1 Antagonists as Migrastatics for Cancer | LAKEHEAD UNIVERSITY (CA) | 2024-10-17 | — | — | US | claimed |
| US-20240317709-A1 | Lysophosphatidic Acid Receptor Antagonists for Breast Cancer Treatment | UNIV LAKEHEAD (CA) | 2024-09-26 | — | — | US | claimed |
| CN-110192294-A | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | 株式会社LG化学 | 2019-08-30 | — | — | CN | claimed |
| US-20240343695-A1 | Lysophosphatidic Acid Receptor 1 Antagonists as Migrastatics for Cancer | LAKEHEAD UNIVERSITY (CA) | 2024-10-17 | — | — | US | disclosed |
| US-20240317709-A1 | Lysophosphatidic Acid Receptor Antagonists for Breast Cancer Treatment | UNIV LAKEHEAD (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | TAXIS PHARMACEUTICALS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | TAXIS PHARMACEUTICALS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-0701546-B1 | AROMATIC ACETYLCHOLINESTERASE INHIBITORS | MERRELL PHARMA INC (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5663448-A | Aromatic acetylcholinesterase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1997-09-02 | — | — | US | disclosed |
| CN-1124953-A | Aromatic acetylcholinesterase inhibitors | MERRELL DOW PHARMA (US) | 1996-06-19 | — | — | CN | disclosed |
| EP-0701546-A1 | AROMATIC ACETYLCHOLINESTERASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0693287-A1 | RNA cleaving or binding oligonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994029255-A1 | AROMATIC ACETYLCHOLINESTERASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| EP-0627400-A1 | Aromatic acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0239643-B1 | PROCESS FOR OXIDIZING 2,6-DIISOPROPYLNAPHTHALENE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4996372-A | In a basic aqueous solution, then acid cleaving in the presence of hydrogen peroxide | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | GABRA1 1476/4885GABRB2 1879/4885CYP3A4 4464/4885 |
| US-20240317709-A1 | Lysophosphatidic Acid Receptor Antagonists for Breast Cancer Treatment | LPAR3, LPAR1, LPAR4 | GABRA1 1101/4885GABRB2 2572/4885CYP3A4 4357/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | GABRA1 3723/4885GABRB2 2660/4885CYP3A4 3282/4885 |
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | GABRA1 3352/4885GABRB2 2810/4885CYP3A4 644/4885 |
| US-20240343695-A1 | Lysophosphatidic Acid Receptor 1 Antagonists as Migrastatics for Cancer | LPAR1, LPAR3, LPAR4 | GABRA1 1783/4885GABRB2 2861/4885CYP3A4 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.